MP Healthcare Venture Management (MPH), a US-based corporate venturing unit on behalf of a Japanese conglomerate, has promoted Takahiro Mukohira (pictured) as president after Hidenobu Ikoma retired.
Mukohira was previously vice-president of MPH, which he started in 2006 as the corporate venturing group of Mitsubishi Tanabe Pharma (MTP) and Mitsubishi Chemical.
Prior to MPH, Mukohira was an executive at MTP and worked on FTY720 (fingolimod), an oral treatment for MS now under review by the US regulators.